A Clearer Future: New Data Shows Myopia Drug SYD-101 Is Most Effective in Young Children, Paving Way for Potential FDA Approval

DEL MAR, Calif. – March 23, 2026 – New clinical trial data has identified the children who stand to benefit most from a promising new eye drop designed to combat the growing epidemic of pediatric myopia, or nearsightedness. Sydnexis, Inc. announced that detailed analyses from its landmark Phase 3 STAR trial show its investigational drug, SYD-101, significantly slows myopia progression, with the most profound effects seen in younger children and those whose vision is worsening rapidly.

The findings, presented at the 51st Annual Meeting of the American Association for Pediatric Ophthalmology and Strabismus (AAPOS), strengthen the company’s case as it seeks to bring the first-ever FDA-approved pharmaceutical treatment for pediatric progressive myopia (PPM) to the U.S. market.

A Focus on Early Intervention

The STAR trial, the largest global study of its kind for pediatric myopia, enrolled 847 children aged 3 to 14 across the United States and Europe. The new data, unveiled by Dr. Tina Rutar on behalf of the STAR Study Group, delved into specific patient subgroups to reveal a crucial narrative: timing is everything.

While SYD-101, a proprietary low-dose atropine formulation, proved effective across the study population, its impact was most significant in younger children. In the 3-to-12-year-old age group, the eye drops reduced myopia progression by a remarkable 47.9% at 12 months and 28.0% over three years compared to a placebo.

“The STAR trial is the largest rigorously designed study of low-dose atropine conducted to date,” said Tina Rutar, MD, a pediatric ophthalmologist and lead author of the AAPOS presentation. “The subgroup analyses tell an important clinical story: young children with a history of myopia progression benefited most from SYD-101.”

The treatment benefit was even more pronounced in children who not only were young but also exhibited fast progression (worsening by more than 0.5 diopters per year) and had mild to moderate baseline myopia. In this specific group, SYD-101 reduced myopia progression by an impressive 56.9% at the 36-month mark. Conversely, teenagers aged 13 to 14 showed minimal progression regardless of treatment, underscoring a critical window for intervention. The drug was also reported to be well-tolerated, with no unexpected safety concerns.

Addressing a Critical Unmet Need

The data arrives at a pivotal moment. Pediatric progressive myopia has become a global health crisis, with prevalence rates soaring. The World Health Organization projects that half the world's population could be myopic by 2050. In North America, that figure is expected to reach nearly 60%. More than just a need for stronger glasses, progressive myopia is a degenerative disease that stretches the eyeball, increasing the risk of severe, sight-threatening conditions later in life, including retinal detachment, glaucoma, and cataracts.

Currently, there are no FDA-approved pharmaceutical options in the United States to slow this progression. Clinicians and parents have relied on a combination of strategies, including specialty optical lenses—like CooperVision's MiSight contact lenses and EssilorLuxottica's recently authorized Essilor Stellest spectacle lenses—and behavioral changes, such as encouraging more outdoor time.

While effective, low-dose atropine has been used off-label, prepared by compounding pharmacies. This practice introduces variability in formulation stability, concentration, and pH, which can affect tolerability and efficacy. SYD-101 was developed specifically to overcome these challenges, offering a standardized, stable, and pH-balanced formulation designed for patient comfort and consistent clinical performance.

“Pediatric myopia is a progressive disease, and the earlier it is identified, the greater the opportunity to intervene in a meaningful way,” said Christie Morse, MD, Executive Vice President of the American Association for Pediatric Ophthalmology and Strabismus. “These findings help clarify which patients stand to benefit most and underscore the importance of timely, evidence-based care to truly change the trajectory of the disease.”

The Strategic Path to a Landmark Approval

For Sydnexis, the new data is a crucial piece of its regulatory strategy. The company is already engaged in discussions with the FDA, and these precise, data-driven insights into which patients benefit most could pave the way for a more targeted and effective treatment paradigm. If approved, SYD-101 would be a landmark product, filling a significant void in the U.S. healthcare landscape.

The drug is already approved in the European Union and the United Kingdom, where it is marketed as Ryjunea® by commercial partner Santen S.A., giving it a track record of regulatory validation.

“While STAR met both its primary endpoint and a key secondary endpoint, the subgroup analyses presented at AAPOS provide important context for understanding which children benefit most from SYD-101,” said Perry Sternberg, Chief Executive Officer of Sydnexis. “Treatment benefit was observed broadly across the study population, with the most meaningful reductions seen in younger children ages 3-12 and fast progressors which aligns with the known natural history of the disease. These results reinforce the importance of early intervention and are integral to our ongoing discussions with the FDA.”

Sydnexis is not alone in the race. Vyluma, Inc. is also in late-stage trials with its own low-dose atropine formulation, NVK-002. However, the comprehensive nature of the STAR trial data and the clear identification of the ideal patient profile provide Sydnexis with a powerful narrative. The focus now shifts to the FDA, as millions of parents and the entire ophthalmology community watch closely, hopeful for a new, powerful tool to protect the vision of a generation of children.